Portal de Periódicos da CAPES

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

2017; Massachusetts Medical Society; Volume: 377; Issue: 14 Linguagem: Inglês

10.1056/nejmoa1709684

1533-4406

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Piotr Rutkowski, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew G. Hill, David Hogg, John B.A.G. Haanen, Matteo S. Carlino, Oliver Bechter, Michele Maio, Iván Márquez‐Rodas, Massimo Guidoboni, Grant A. McArthur, Célèste Lebbe, Paolo A. Ascierto, Georgina V. Long, Jonathan Cebon, Jeffrey A. Sosman, Michael A. Postow, Margaret K. Callahan, Damian Walker, Linda Rollin, Rafia Bhore, F. Stephen Hodi, James Larkin,

Immunotherapy and Immune Responses

Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial.